Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Options

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Dec 09, 2023 6:22pm

116 Views

Post# 35776522

RE:Options

Of course, most names on the list are no longer insiders or involved with ONC.

So, they may have had the options converted as part of their exit plan, and it is possible the numbers are not relevant. I'm not sure how this works with reporting requirements in Canada.

But do pay attention to MC and KL. Those two names are certainly of interest.

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it